U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H29N3O8
Molecular Weight 499.5131
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERDEXMETHYLPHENIDATE

SMILES

COC(=O)[C@@H]([C@H]1CCCCN1C(=O)OC[N+]2=CC(=CC=C2)C(=O)N[C@@H](CO)C([O-])=O)C3=CC=CC=C3

InChI

InChIKey=UBZPNQRBUOBBLN-PWRODBHTSA-N
InChI=1S/C25H29N3O8/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32)/t19-,20+,21+/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H29N3O8
Molecular Weight 499.5131
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

CNS Activity

CNS Active
4002
Curator's Comment: Dexmethylphenidate is a central nervous system (CNS) stimulant

Originator

Approval Year

2001
187
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 161.0 nM [Ki]
Inhibitor
8504
 206.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
FOCALIN

Approved Use

Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
22.13 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
23.72 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.7 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
131.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
120.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79.8 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.81 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.68 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Other AEs: Vomiting, Agitation...
Other AEs:
Vomiting
Agitation
Tremor
Hyperreflexia
Muscle twitching
Convulsions
Euphoria
Confusion
Hallucinations
Delirium
Sweating
Flushing
Headache
Hyperpyrexia
Tachycardia
Palpitations
Cardiac arrhythmias
Hypertension
Mydriasis
Mucosal dryness
Rhabdomyolysis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Disc. AE: Twitching, Anorexia...
AEs leading to
discontinuation/dose reduction:
Twitching (1%)
Anorexia (1%)
Insomnia (1%)
Tachycardia (1%)
Insomnia (1.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Disc. AE: Cardiac disorders, Stroke...
Other AEs: Increased blood pressure, Heart rate increased...
AEs leading to
discontinuation/dose reduction:
Cardiac disorders (grade 3-5)
Stroke (grade 3-5)
Myocardial infarction (grade 3-5)
Seizures
Raynaud's phenomenon
Other AEs:
Increased blood pressure
Heart rate increased
Psychotic symptom (grade 3-5)
Psychotic symptom
Manic symptom
Aggression
Growth suppression
Priapism
Erection prolonged
Vascular disorders
Visual disturbance
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Disc. AE: Feeling jittery, Anorexia...
AEs leading to
discontinuation/dose reduction:
Feeling jittery (1.8%)
Anorexia (1.2%)
Anxiety (1.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Agitation
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Cardiac arrhythmias
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Confusion
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Convulsions
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Delirium
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Euphoria
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Flushing
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hallucinations
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Headache
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hyperpyrexia
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hyperreflexia
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hypertension
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Mucosal dryness
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Muscle twitching
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Mydriasis
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Palpitations
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Rhabdomyolysis
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Sweating
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Tachycardia
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Tremor
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Vomiting
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Anorexia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Insomnia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Tachycardia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Twitching 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Insomnia 1.8%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Aggression
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Erection prolonged
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Growth suppression
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Heart rate increased
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Increased blood pressure
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Manic symptom
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Priapism
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Psychotic symptom
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Vascular disorders
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Visual disturbance
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Raynaud's phenomenon Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Seizures Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Psychotic symptom grade 3-5
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Cardiac disorders grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Myocardial infarction grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Stroke grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Anorexia 1.2%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Anxiety 1.2%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Feeling jittery 1.8%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C8
1057

CYP2C19
2057

CYP2E1
1060

CYP3A
227
esterase
74

CES2
33

P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2E1
1146
 no
CYP3A
317
 no
CYP2D6
2546
 no
no (co-administration study)
Comment: Clinically, methylphenidate coadministration did not increase plasma concentrations of the CYP2D6 substrate desipramine.
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES2
33
 no
P-gp
2052
 weak
esterase
74
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51860
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51860
ZINC
ZINC000000896711
http://zinc15.docking.org/substances/ZINC000000896711
PubMed

PubMed

TitleDatePubMed
The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
2002
A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
2004 Nov
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
2004 Winter
A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
2004 Winter
Attention deficit/hyperactivity disorder: pharmacotherapy.
2005 Jan
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
2005 Jul
Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core.
2005 Mar
ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine.
2006
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
2006
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
2006 Dec 20
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
2006 Jan
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
2006 Jun 9
The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.
2007 Aug
Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
2007 Dec
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
2007 Jun 15
Psychopharmacology of ADHD in pediatrics: current advances and issues.
2009
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
2009 Aug
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.
2009 Jun 29
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).
2009 Jun 8
Dexmethylphenidate for attention deficit hyperactivity disorder.
2009 Nov
Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.
2010 Apr
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
2010 Aug
Use of psychostimulants in patients with dementia.
2010 Oct
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.
2010 Sep 3
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.
2011 Jan 1
Patents

Patents

JP2009526755A
475
JP2011510954A
147

Sample Use Guides

In Vivo Use Guide
Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5 mg/day (2.5 mg twice daily). Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration: Oral
In Vitro Use Guide
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Substance Class Chemical
Created
by admin
on Tue Apr 01 21:08:42 GMT 2025
Edited
by admin
on Tue Apr 01 21:08:42 GMT 2025
Record UNII
0H8KZ470DW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERDEXMETHYLPHENIDATE
USAN   INN  
Official Name English
PYRIDINIUM, 3-((((1S)-1-CARBOXY-2-HYDROXYETHYL)AMINO)CARBONYL)-1-(((((2R)-2-((1R)-2-METHOXY-2-OXO-1-PHENYLETHYL)-1-PIPERIDINYL)CARBONYL)OXY)METHYL)-
Preferred Name English
KP-415 INNER SALT
Code English
serdexmethylphenidate [INN]
Common Name English
SERDEXMETHYLPHENIDATE [USAN]
Common Name English
N-(1-((((2R)-2-((1R)-2-METHOXY-2-OXO-1-PHENYLETHYL)PIPERIDINE-1-CARBONYL)OXY)METHYL)PYRIDIN-1-IUM-3-CARBONYL)-L-SERINATE
Systematic Name English
Serdexmethylphenidate [WHO-DD]
Common Name English
Classification Tree Code System Code
DEA NO. 1729
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
FDA ORPHAN DRUG 878522
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
Code System Code Type Description
CAS
2014450-84-9
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
ALTERNATIVE
SMS_ID
300000005913
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
CAS
1996626-29-9
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
FDA UNII
0H8KZ470DW
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
RXCUI
2562176
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
INN
10916
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
PUBCHEM
134823895
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
NCI_THESAURUS
C166420
Created by admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
PRIMARY
Related Record Type Details
Structure of SERDEXMETHYLPHENIDATE
EXCRETED UNCHANGED
URINE
Structure of SERDEXMETHYLPHENIDATE CHLORIDE
SALT/SOLVATE -> PARENT
Structure of SERDEXMETHYLPHENIDATE
EXCRETED UNCHANGED
FECAL
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Related Record Type Details
Structure of DEXMETHYLPHENIDATE
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
Structure of DEXMETHYLPHENIDATE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Structure of SERDEXMETHYLPHENIDATE
FASTED STATE
PHARMACOKINETIC
SINGLE DOSE ADMINISTRATION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Structure of SERDEXMETHYLPHENIDATE
IN HEALTHY ADULT SUBJECTS
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Structure of SERDEXMETHYLPHENIDATE
after AZSTARYS administration
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966